Rule 4.7B
Appendix 4C
For personal use only
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Name of entity
SomnoMed Limited
ABN
35 003 255 221
Quarter ended ("current quarter")
31st March 2022
Consolidated statement of cash flows | Current quarter $A'000 | Year to date (9 months) $A'000 |
| 16,759 (29) (8,334) (1,145) - (6,461) (2,833) - 1 (40) (157) - - | 51,639 (87) (19,514) (3,557) - (21,897) (7,902) - 11 (300) (328) - - |
(2,240) | (1,934) |
2.
Cash flows from investing activities
2.1
Payments to acquire:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f) other non-current assets
(27)
(462)
(3,337)
(6,158)
ASX Listing Rules Appendix 4C (01/12/19)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
For personal use only
Consolidated statement of cash flows | Current quarter $A'000 | Year to date (9 months) $A'000 |
| - - | - 317 |
(3,365) | (6,304) |
| 14 - 4,340 - (418) | 14 - 4,340 - (1,494) |
3,937 | 2,861 |
4.
Net increase / (decrease) in cash and cash equivalents for the period
4.1
Cash and cash equivalents at beginning of period
4.2
Net cash from / (used in) operating activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities (item 2.6 above)
17,570 (2,240)
21,110 (1,934)
(3,365)
(6,304)
ASX Listing Rules Appendix 4C (01/12/19)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
For personal use only
Consolidated statement of cash flows | Current quarter $A'000 | Year to date (9 months) $A'000 | |
4.4 4.5 4.6 | Net cash from / (used in) financing activities (item 3.10 above) Effect of movement in exchange rates on cash held Cash and cash equivalents at end of period | 3,937 (1,123) | 2,861 (954) |
14,779 | 14,779 |
5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 |
| 7,727 317 4,340 2,395 | 14,859 317 2,395 |
14,779 | 17,571 |
6. Payments to related parties of the entity and their associates
6.1 Aggregate amount of payments to related parties and their associates included in item 1
6.2 Aggregate amount of payments to related parties and their associates included in item 2
Current quarter
$A'000
229
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments
6.1 Includes payments in relation to the Managing Director pursuant to his employment contract and non-executive directors' fees.
ASX Listing Rules Appendix 4C (01/12/19)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
7. Financing facilities
Note: the term "facility' includes all forms of financing arrangements available to the entity.
Add notes as necessary for an understanding of the sources of finance available to the entity.
For personal use only
8.
Estimated cash available for future operating activities
$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)
8.2 Cash and cash equivalents at quarter end (Item 4.6)
8.3 Unused finance facilities available at quarter end (Item 7.5)
8.4 Total available funding (Item 8.2 + Item 8.3)
8.5 Estimated quarters of funding available (Item 8.4 divided by
Item 8.1)
(2,240) 14,779 - 14,779
6.59
7.1 Loan facilities (unsecured)
7.2 Credit standby arrangements
7.3 Other (please specify)
7.4 Total financing facilities
Total facility amount at quarter end $A'000
Amount drawn at quarter end
$A'000
2,395
2,395
4,340
4,340
6,735
6,735
7.5 Unused financing facilities available at quarter end
-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.
Loan Facilities:
o In March 2020, SomnoMed AG (Switzerland) secured a CHF 0.5 million (A$0.756 million) Government-backed unsecured loan facility with Credit Suisse (maturity of 5 years). The interest payable is currently at 0.50% per annum. This loan expires on 26 February 2025;
o In May 2020, SomnoMed France SAS (France) secured a EUR 0.515 million (A$0.832 million Government-backed unsecured loan facility with Société Générale. The interest payable is at 0.5% per annum in the first year (after a grace period of 12 months. Maturity of 5 years). This loan expires on 20 May 2026;
o In June 2020, SomnoMed Germany GmbH (Germany) secured a EUR 0.5 million (A$0.807 million) Government-backed unsecured loan facility with Commerzbank (maturity of up to 6 years). The interest payable is 3% per annum. This loan expires on 30 June 2030.
Credit Standby arrangements:
o In June 2019, SomnoMed Limited secured a EUR 3 million (A$4.3 million) credit facility, in the form of an overdraft facility, with HSBC France, Amsterdam Branch. The overdraft facility comprises an interest calculated at the Main Refinancing Operations rate published by the European Central Bank (provided that, if such interest rate is less than zero, it shall be deemed to be zero), increased with the applicable margin of 2.75%. The Main Refinancing Operations Rate is currently at 0%. The facility was fully drawn by SomnoMed in March-22 and converted at the exchange rate on 31st March 2022.
ASX Listing Rules Appendix 4C (01/12/19)
Page 4
+ See chapter 19 of the ASX Listing Rules for defined terms.
8.6
If Item 8.5 is less than 2 quarters, please provide answers to the following questions:
1.
Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
For personal use only
Answer:
2.
Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
Answer:
3.
Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer:
ASX Listing Rules Appendix 4C (01/12/19)
Page 5
+ See chapter 19 of the ASX Listing Rules for defined terms.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Somnomed Limited published this content on 26 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 00:54:10 UTC.